These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 9223638)

  • 1. Molecular characterization of the hdm2-p53 interaction.
    Böttger A; Böttger V; Garcia-Echeverria C; Chène P; Hochkeppel HK; Sampson W; Ang K; Howard SF; Picksley SM; Lane DP
    J Mol Biol; 1997 Jun; 269(5):744-56. PubMed ID: 9223638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel mdm2 binding peptides by phage display.
    Böttger V; Böttger A; Howard SF; Picksley SM; Chène P; Garcia-Echeverria C; Hochkeppel HK; Lane DP
    Oncogene; 1996 Nov; 13(10):2141-7. PubMed ID: 8950981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitric oxide-mediated inhibition of Hdm2-p53 binding.
    Schonhoff CM; Daou MC; Jones SN; Schiffer CA; Ross AH
    Biochemistry; 2002 Nov; 41(46):13570-4. PubMed ID: 12427017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a binding assay for p53/HDM2 by using homogeneous time-resolved fluorescence.
    Kane SA; Fleener CA; Zhang YS; Davis LJ; Musselman AL; Huang PS
    Anal Biochem; 2000 Feb; 278(1):29-38. PubMed ID: 10640350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.
    Chène P; Fuchs J; Bohn J; García-Echeverría C; Furet P; Fabbro D
    J Mol Biol; 2000 May; 299(1):245-53. PubMed ID: 10860736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining the molecular basis of Arf and Hdm2 interactions.
    Bothner B; Lewis WS; DiGiammarino EL; Weber JD; Bothner SJ; Kriwacki RW
    J Mol Biol; 2001 Nov; 314(2):263-77. PubMed ID: 11718560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor protects p53 from deactivation by human double minute-2.
    Liu G; Schwartz JA; Brooks SC
    Cancer Res; 2000 Apr; 60(7):1810-4. PubMed ID: 10766163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abundant expression of spliced HDM2 in Hodgkin lymphoma cells does not interfere with p14(ARF) and p53 binding.
    Stürzenhofecker B; Schlott T; Quentin T; Kube D; Jung W; Trümper L
    Leuk Lymphoma; 2003 Sep; 44(9):1587-96. PubMed ID: 14565663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helical beta-peptide inhibitors of the p53-hDM2 interaction.
    Kritzer JA; Lear JD; Hodsdon ME; Schepartz A
    J Am Chem Soc; 2004 Aug; 126(31):9468-9. PubMed ID: 15291512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR.
    Parks DJ; Lafrance LV; Calvo RR; Milkiewicz KL; Gupta V; Lattanze J; Ramachandren K; Carver TE; Petrella EC; Cummings MD; Maguire D; Grasberger BL; Lu T
    Bioorg Med Chem Lett; 2005 Feb; 15(3):765-70. PubMed ID: 15664854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.
    Linares LK; Hengstermann A; Ciechanover A; Müller S; Scheffner M
    Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12009-14. PubMed ID: 14507994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length.
    Lai Z; Auger KR; Manubay CM; Copeland RA
    Arch Biochem Biophys; 2000 Sep; 381(2):278-84. PubMed ID: 11032416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells.
    Chène P; Fuchs J; Carena I; Furet P; García-Echeverría C
    FEBS Lett; 2002 Oct; 529(2-3):293-7. PubMed ID: 12372616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CBP/p300 TAZ1 domain in its native state is not a binding partner of MDM2.
    Matt T; Martinez-Yamout MA; Dyson HJ; Wright PE
    Biochem J; 2004 Aug; 381(Pt 3):685-91. PubMed ID: 15154850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway.
    Zhang Y; Wolf GW; Bhat K; Jin A; Allio T; Burkhart WA; Xiong Y
    Mol Cell Biol; 2003 Dec; 23(23):8902-12. PubMed ID: 14612427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits.
    Dudgeon DD; Shinde S; Hua Y; Shun TY; Lazo JS; Strock CJ; Giuliano KA; Taylor DL; Johnston PA; Johnston PA
    J Biomol Screen; 2010 Aug; 15(7):766-82. PubMed ID: 20639499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formation of disulfide bond in p53 correlates with inhibition of DNA binding and tetramerization.
    Sun XZ; Vinci C; Makmura L; Han S; Tran D; Nguyen J; Hamann M; Grazziani S; Sheppard S; Gutova M; Zhou F; Thomas J; Momand J
    Antioxid Redox Signal; 2003 Oct; 5(5):655-65. PubMed ID: 14580323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors.
    Lai Z; Yang T; Kim YB; Sielecki TM; Diamond MA; Strack P; Rolfe M; Caligiuri M; Benfield PA; Auger KR; Copeland RA
    Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14734-9. PubMed ID: 12407176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-peptides with improved affinity for hDM2 and hDMX.
    Harker EA; Daniels DS; Guarracino DA; Schepartz A
    Bioorg Med Chem; 2009 Mar; 17(5):2038-46. PubMed ID: 19211253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of two peptide epitopes on Mdm2 oncoprotein that affect p53 degradation.
    Balass M; Kalef E; Maya R; Wilder S; Oren M; Katchalski-Katzir E
    Peptides; 2002 Oct; 23(10):1719-25. PubMed ID: 12383858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.